6 completed, 1 recruiting, 1 suspended, 1 unknown. 3 Phase 1, 2 Not applicable, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Anaphylactic Reaction: new trials by email Literature Review of Anaphylactic Reaction trials Research Report on Anaphylactic Reaction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Steroid Use in Treatment of Allergic Reactions to Food Antihistamines, Systemic corticosteroids, Adrenaline (rescue medication) - Anaphylactic Reaction, Anaphylaxis | Phase 4 | Recruiting | Johannes Trueck | 160 | 2026-01-26 | 2026-01-27 |
| Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants. Epinephrine, Placebo - Anaphylactic Reaction | Phase 1 | Completed | De Motu Cordis | 24 | 2023-10-24 | 2024-08-20 |
| Standardised Drug Provocation Testing in Perioperative Hypersensitivity Full dose DPT with propofol, Full dose DPT with ketamine, Full dose DPT with etomidate - Allergic Reaction, Hypersensitivity | Not applicable | Completed | University Hospital, Antwerp | 50 | 2023-10-23 | 2025-09-08 |
| Comparative Bioavailability of Intranasal Epinephrine A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg - Anaphylaxis, Anaphylactic Reaction | Phase 1 / Phase 2 | Completed | Nasus Pharma | 12 | 2023-08-22 | 2025-06-18 |
| Design, Implementation and Evaluation of the Guided Observer Role in Clinical Simulation Educational intervention. observation guide - Anaphylactic Reaction | Not applicable | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 123 | 2023-05-10 | 2024-05-08 |
| Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg) - Anaphylactic Reaction | Phase 1 | Completed | De Motu Cordis | 23 | 2022-01-06 | 2023-07-24 |
| Allergy and COVID-19 Vaccines COVID-19 Vaccines - Anaphylactic Reaction, Vaccine Reaction | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 117 | 2021-09-15 | 2026-09-17 |
| Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study Xueshuantong-Injection - Adverse Drug Event, Adverse Drug Reactions | Unknown | Zhong Wang | 30000 | 2019-02-18 | 2021-07-07 | |
| Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study Breviscapine Powder-Injection - Adverse Drug Event, Adverse Drug Reaction | Suspended | Zhong Wang | 20000 | 2015-09-01 | 2021-04-08 |
Anaphylaxis (9) · Drug-Related Side Effects and Adverse Reactions (2) · Drug Hypersensitivity (1) · Food Hypersensitivity (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1)
Immune System Diseases (9) · Hypersensitivity (8) · Hypersensitivity, Immediate (8) · Chemically-Induced Disorders (3) · Drug-Related Side Effects and Adverse Reactions (1)
Epinephrine (4) · 2019-nCoV Vaccine mRNA-1273 (1) · Betamethasone (1) · COVID-19 Vaccines (1) · Dimethindene (1) · Histamine Antagonists (1) · Inhalation (1) · Prednisolone (1) · levocetirizine (1)
De Motu Cordis (2) · Zhong Wang (2) · Assistance Publique - Hôpitaux de Paris (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Johannes Trueck (1) · Nasus Pharma (1) · University Hospital, Antwerp (1)
Australia (2) · China (2) · Belgium (1) · France (1) · Israel (1) · Spain (1) · Switzerland (1)
Zhong Wang, M.D. (2) · Jinmin Liu, M.D. (1) · Lizarbe Marta, PhD (1) · Peter O'Neil (1) · Peter O'Neill (1) · Vera Saldien, MD,PhD (1) · Xin-zhi Wang (1) · Yoseph Caraco, Professor (1)